SOLID DISPERSION of 4- (3-ETHOXY-4-HYDROXIBENZIL) -5-OXO-5,6-DIHYDRO-4H- [1,3,4] -THIADIAZINE-2- (2,4-DIFLUOROPHENYL) -CARBOXAMIDE FOR PRODUCING PHARMACEUTICAL FORMULATION AND METHOD OF TREATMENT OF CHRONIC INFECTIOUS DISEASES Russian patent published in 2021 - IPC A61K31/549 A61K47/30 A61P31/04 

FIELD: pharmaceutical industry and medicine.

SUBSTANCE: invention relates to chemical and pharmaceutical industry and medicine, in particular to solid dispersion for production of pharmaceutical formulations. It comprises the active ingredient 4- (3-ethoxy-4-hydroxybenzyl) -5-oxo-5,6-dihydro-4H- [1,3,4] -thiadiazine-2- (2,4-difluorophenyl) -carboxamide and at least one pharmaceutically acceptable polymer, which is contained in a solid dispersion at a mass ratio of the active substance to the polymer from 1: 1 to 1:10, while the active substance is contained in amorphous form or in amorphous form with an admixture of microcrystalline and crystalline phases. The invention also relates to a method for treatment of chronic infections of the respiratory system caused by Pseudomonas aeruginosa antibiotic-resistant strains. The method comprises the use of the specified solid dispersion in an effective therapeutic dose for humans in an amount of 1 to 4 milligrams per kilogram body weight (mpk) equivalent to the active ingredient.

EFFECT: technical result consists in obtaining a solid dispersion with increased bioavailability in comparison with the active substance in crystalline form and therapeutic efficiency in relation to infections caused by Pseudomonas aeruginosa antibiotic-resistant strains.

8 cl, 9 ex, 13 tbl, 18 dwg